Maribavir: Phase II started

ViroPharma began a European Phase II trial to compare 400, 800 and 1,200 mg oral maribavir twice daily vs. Valcyte valganciclovir for up to 12 weeks in about 160 patients who received hematopoietic stem cell or solid organ transplants and have demonstrated CMV viremia but do not have CMV organ disease. Maribavir has Orphan Drug designation in the U.S. to treat clinically significant CMV viremia and disease in at-risk patients. ViroPharma has exclusive, worldwide rights outside Japan to GlaxoSmithKline's maribavir under a 2003 deal (see BioCentury, Aug. 18, 2003). ...